PARIS--(BUSINESS WIRE)--Nanobiotix (Euronext: NANO / ISIN: FR0011341205), announced today that the Independent Data Monitoring Committee (IDMC) has reviewed the data of the first 6 patients treated in the phase I Study with the lead product NBTXR3 for the treatment of advanced Soft Tissue Sarcoma of the extremity. Based on the review of the safety data, the IDMC has unanimously recommended continuing the enrollment in the study according to the protocol. This trial is realized in the Institut Gustave Roussy, France. “This milestone is crucial for NANOBIOTIX” says Laurent Levy, CEO and co-founder of Nanobiotix. “It is in accordance with our expectations concerning our NanoXray products’ risk profile. After our successful IPO, we are happy to deliver this first milestone to all our investors and subscribers who have had confidence in the company. We intend to continue to deliver with our breakthrough technology to bring those products to patients rapidly and efficiently. This initial step is “derisking” our approach and gives us confidence to expend the clinical development to different indications.”
